Equities analysts predict that Abbott Laboratories (NYSE:ABT) will announce earnings of $0.58 per share for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Abbott Laboratories’ earnings. The lowest EPS estimate is $0.57 and the highest is $0.59. Abbott Laboratories reported earnings per share of $0.48 in the same quarter last year, which suggests a positive year-over-year growth rate of 20.8%. The company is expected to report its next quarterly earnings report on Wednesday, April 18th.

On average, analysts expect that Abbott Laboratories will report full-year earnings of $2.86 per share for the current fiscal year, with EPS estimates ranging from $2.85 to $2.89. For the next year, analysts expect that the company will report earnings of $3.21 per share, with EPS estimates ranging from $3.15 to $3.27. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The firm had revenue of $7.59 billion for the quarter, compared to the consensus estimate of $7.38 billion. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The company’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same period last year, the business posted $0.65 EPS.

Several equities analysts recently weighed in on ABT shares. ValuEngine downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays reiterated a “buy” rating and set a $66.00 target price on shares of Abbott Laboratories in a research report on Monday, January 8th. BTIG Research downgraded Abbott Laboratories from a “buy” rating to a “neutral” rating in a research report on Monday, January 22nd. They noted that the move was a valuation call. Stifel Nicolaus lifted their target price on Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, October 19th. Finally, Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Tuesday, October 31st. Eight investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Abbott Laboratories currently has a consensus rating of “Buy” and an average target price of $65.47.

In other news, insider Daniel Gesua Sive Salvadori sold 71,157 shares of Abbott Laboratories stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $55.00, for a total value of $3,913,635.00. Following the sale, the insider now directly owns 144,955 shares of the company’s stock, valued at $7,972,525. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Miles D. White sold 276,886 shares of Abbott Laboratories stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total value of $15,065,367.26. Following the completion of the sale, the chairman now directly owns 3,677,913 shares in the company, valued at $200,115,246.33. The disclosure for this sale can be found here. Insiders sold 445,615 shares of company stock worth $24,666,341 over the last 90 days. Company insiders own 0.76% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. St. Louis Trust Co increased its holdings in shares of Abbott Laboratories by 0.4% in the second quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock worth $238,000 after purchasing an additional 20 shares during the last quarter. Lakeview Capital Partners LLC increased its stake in Abbott Laboratories by 0.6% during the second quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock worth $277,000 after acquiring an additional 33 shares during the last quarter. Cobblestone Capital Advisors LLC NY increased its stake in Abbott Laboratories by 0.3% during the second quarter. Cobblestone Capital Advisors LLC NY now owns 16,511 shares of the healthcare product maker’s stock worth $803,000 after acquiring an additional 56 shares during the last quarter. Lee Financial Co increased its stake in Abbott Laboratories by 1.7% during the second quarter. Lee Financial Co now owns 3,388 shares of the healthcare product maker’s stock worth $165,000 after acquiring an additional 57 shares during the last quarter. Finally, Ronald Blue & Co. LLC increased its stake in Abbott Laboratories by 0.9% during the second quarter. Ronald Blue & Co. LLC now owns 8,368 shares of the healthcare product maker’s stock worth $407,000 after acquiring an additional 71 shares during the last quarter. 70.61% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories (ABT) traded up $0.24 during midday trading on Wednesday, reaching $57.41. The company had a trading volume of 8,219,430 shares, compared to its average volume of 8,023,253. The stock has a market capitalization of $100,590.00, a P/E ratio of 288.95, a PEG ratio of 1.72 and a beta of 1.55. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 12 month low of $42.31 and a 12 month high of $64.60.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 1.95%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, January 11th. Abbott Laboratories’s payout ratio is presently 560.00%.

WARNING: “Zacks: Analysts Expect Abbott Laboratories (ABT) to Announce $0.58 Earnings Per Share” was published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/zacks-analysts-expect-abbott-laboratories-abt-to-announce-0-58-earnings-per-share/1861843.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.